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Background: Immunohistochemistry (IHC) is a well-established method for the analysis of protein expression in tissue
specimens and constitutes one of the most common methods performed in pathology laboratories worldwide.
However, IHC is a multi-layered method based on subjective estimations and differences in staining and interpretation
has been observed between facilities, suggesting that the analysis of proteins on tissue would benefit from protocol
optimization and standardization. Here we describe how the emerging and operator independent tool of real-time
immunohistochemistry (RT-IHC) reveals a time resolved description of antibody interacting with target protein in
formalin fixed paraffin embedded tissue. The aim was to understand the technical aspects of RT-IHC, regarding
generalization of the concept and to what extent it can be considered a quantitative method.
Results: Three different antibodies labeled with fluorescent or radioactive labels were applied on nine different tissue
samples from either human or mouse, and the results for all RT-IHC analyses distinctly show that the method is
generally applicable. The collected binding curves showed that the majority of the antibody-antigen interactions did
not reach equilibrium within 3 hours, suggesting that standardized protocols for immunohistochemistry are sometimes
inadequately optimized. The impact of tissue size and thickness as well as the position of the section on the glass petri
dish was assessed in order for practical details to be further elucidated for this emerging technique. Size and location
was found to affect signal magnitude to a larger extent than thickness, but the signal from all measurements were still
sufficient to trace the curvature. The curvature, representing the kinetics of the interaction, was independent of thickness,
size and position and may be a promising parameter for the evaluation of e.g. biopsy sections of different sizes.
Conclusions: It was found that RT-IHC can be used for the evaluation of a number of different antibodies and tissue
types, rendering it a general method. We believe that by following interactions over time during the development of
conventional IHC assays, it becomes possible to better understand the different processes applied in conventional IHC,
leading to optimized assay protocols with improved sensitivity.
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Immunohistochemistry (IHC) is a widely used technique
for diagnostic and research purposes [1]. Its central role in
classification of diseases by evaluation of receptors and
other cellular components in biopsies and surgical resec-
tions has made IHC one of the most important methods
in pathology [2].* Correspondence: hanna.bjorkelund@bms.uu.se
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stated.The basics of IHC are to stain a thin representative tissue
section and evaluate the intensity and localization of the
staining in order to understand e.g. antigen expression.
Estimation of the level and distribution of expression is
subjectively performed by trained personnel through visual
inspection in the microscope, and commonly staining posi-
tivity is described as -, +, ++ and +++. The technique pro-
vides superior spatial resolution, but is operator dependent
and further relies on multi-layered end-point measure-
ments which increase the risk of inaccurate report of anti-
gen expression. One example is the reporting of HER2
expression in bladder cancer (2-79%) [3,4] and ovarianLtd. This is an Open Access article distributed under the terms of the Creative
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have been discussed more intensively the last couple of
years and there is a general call for standardization [7,8].
Recently, Gedda et al. reported a method allowing the
time resolved measurement of the interaction between a
radiolabeled antibody and its antigen as expressed in
tissue – real-time IHC (RT-IHC) [9]. The use of real-time
measurements compared to manual end-point measure-
ments has many benefits, such as an inherent and imme-
diate quality control where problems with an assay can be
detected as e.g. irregularities in the binding curve. The
time-resolution opens up for estimations of time to equi-
librium, reducing the risk of interrupting the incubation
prematurely. Thus, time resolved detection technologies
are particularly useful when developing novel assays and
when troubleshooting existing assays. The possibility to
follow the interaction minute by minute can not only
reveal when equilibrium occurs, but may also pinpoint
which of several components in a multilayer technique
that is the limiting factor [10]. It has further been demon-
strated that the curvature of the real-time binding trace,
corresponding to the kinetics of the antibody-antigen
interaction, contain important information about the tis-
sue, where e.g. non-specific binding can be corrected for
based on its distinct time-resolved binding pattern. For
example, in a second study by Gedda et. al., a clear correl-
ation was found between the curve shape and the HER2
scoring of biopsy material from twenty breast cancer
patients [11], independent of signal amplitude.
All measurements conducted in this study were done
using LigandTracer® instruments. LigandTracer was ini-
tially developed for monitoring protein-cell interactions in
real time [12-16], but is equally applicable to evaluate
interactions to paraffin embedded tissue [9] or between
purified proteins [17]. Although the applications vary, the
basic principle of the instrument is the same. A target area
of a Petri dish is created by e.g. mounting tissue sections
or seeding adherent cells. The dish is placed on a tilted,
rotating support and a solution with a fluorescently or
radioactively labeled molecule is added. The signal detec-
tion is performed in the elevated area of the dish and
followed over time. A target free area of the dish is used
as a reference to continuously subtract the background
signal.
In this work three different antigens were analyzed:
SATB2, RBM3 and HER2. Low expression of the cold
shock RNA-binding protein RBM3 is associated with
tumor progression and poor prognosis in malignant mel-
anoma [18]. The DNA-binding SATB2 protein is known
to be involved in transcriptional regulation and chroma-
tin remodeling [19] and mutations of its corresponding
gene has been correlated with cleft palate and cognitive
defects [20]. The HER2 membrane receptor is a member
of the epidermal growth factor receptor family and isoverexpressed in e.g. breast cancer [21], making it an
important target for anti-cancer therapies such as the
therapeutic antibody Herceptin® [22].
The previous work with RT-IHC has been done with
one single antibody, one radioactive label and mostly
mouse tissue or human xenograft in mouse. This work
aimed at investigating if the method was generally ap-
plicable by the use of different antigens, antibodies, la-
bels (including two fluorophores) and tissue types. The
setup of the two previous studies was also included
[9,11], as a link between old and new data. All other tis-
sues were chosen to represent strong and weak staining
as explored using conventional IHC. Use of fluorescent
labels is essential for making the assay accessible for all
laboratories, as radioactivity requires proper facilities
and special type of instruments. This paper further eval-




Tissues were selected to represent a range of staining in-
tensities for the anti-RBM3 and anti-SATB2 antibodies
(Figure 1). For the antibody binding to RBM3, nasophar-
ynx and urinary bladder were selected for representing
strong staining, testis for representing strong staining in
only on a subset of the cells in the tissue, and tonsil for
signs of only weak staining. For the anti-SATB2 anti-
body, colon displayed strong staining, tonsil and liver
heterogenous staining with scattered areas of positivity
and heart muscle was negative. The tissues used as posi-
tive and negative control for HER2 in previous studies
were included as well [9,11]. The anti-HER2 antibody
stained the SKOV3 xenograft strongly and mouse liver
tissue weakly.
The impact of different incubation times
The effect of varying primary antibody pre-incubation
times (1 h, 3 h or 24 h) prior to measurement of labeled
secondary antibody was conducted using 8 nM un-
labeled anti-RBM3 antibody, with the RBM3 high ex-
pressing nasopharynx and the RBM3 low expressing
tonsil (Figure 2). Clear binding traces were collected in
the instrument LigandTracer Green using 6.5 nM fluo-
rescently labeled secondary antibody. One hour pre-
incubation with 8 nM anti-RBM3 antibody produced
the lowest signals, suggesting that more than one hour
is beneficial to obtain high signal levels. Irrespective of
pre-incubation time, the signal from tonsil was small in
comparison to the signal from nasopharynx, which is in
line with the results from IHC analysis presented in
Figure 1. The secondary antibody required more than
300 minutes to reach equilibrium at the used concentra-
tion (6.5 nM).
Figure 1 Tissue staining of RBM3, SATB2 and HER2. Staining of RBM3 in A) nasopharynx, B) urinary bladder, C) testis, D) tonsil, SATB2 in
E) colon, F) tonsil, G) liver, H) heart muscle, and HER2 in I) SKOV3 xenograft, J) mouse liver. The primary antibody was incubated for 30 minutes
in all stainings, according to the established protocol. The scale bar indicates 100 μm.
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in RT-IHC
A panel of tissues was used for comparing the real-time
binding of 6.5 nM fluorescently labeled secondary anti-
body to tissues pre-incubated (3 h) with 8 nM unlabeled
anti-RBM3 antibody (Figure 3A). Nasopharynx yielded the
highest signal and tonsil the lowest. For urinary bladder
and testis, the signals were slightly lower than for naso-
pharynx, which is in agreement with the tissue staining.
The results were similar when monitoring the binding ofFigure 2 RT-IHC results showing RBM3 expression using
fluorescently labeled secondary antibody. The binding of
secondary antibody in nasopharynx (black lines) and tonsil (grey
lines) after 1 h (dotted lines), 3 h (dashed lines) and 24 h (solid lines)
of pre-incubation with a RBM3-binding antibody. I = Fluorescent
intensity units.labeled primary antibody (anti-RBM3) at increasing con-
centrations (6, 12, 21 nM), although with a somewhat
higher signal for testis (Figure 3B). The time for 6 nM of
primary antibody to reach equilibrium was approximately
100 minutes, as estimated from Figure 3B.
A similar pair of experiments was conducted towards
SATB2 (Figure 3C, D). In both cases, colon yielded the
highest signal and tonsil the lowest. The secondary anti-
body produced low signals for heart muscle and liver
(Figure 3C), but the signal level of liver was comparable
to that of colon during the detection of labeled primary
antibody (Figure 3D). Time for 6 nM of the anti-SATB2
antibody to reach equilibrium was greater than 100 minutes
(Figure 3D).
The binding of anti-HER2 antibody to SKOV3 xenograft
and mouse liver
The concentration of 125I-labeled anti-HER2 antibody was
step-wised increased (1 nM, 3 nM, 9 nM; 10-20 h per con-
centration) in a dish containing HER2 high expressing
SKOV3 xenograft and HER2 low expressing mouse liver,
followed by a dissociation phase (0 nM). A clear interaction
was seen to the SKOV3 xenograft (black curve), but to
a much lower extent to the mouse liver tissue. The in-
teraction was slow, requiring approximately 24 h to
reach equilibrium for the lowest concentration (Figure 4A),
which is in line with what has previously been observed
[9]. The significant signal increase upon addition of
Figure 3 RT-IHC results, using fluorescently labeled primary or secondary antibody. Binding traces produced in LigandTracer, depicting the
binding of A) Alexa Fluor 488 labeled anti-mouse antibody after 3 h pre-incubation with anti-RBM3 antibody, B) direct binding of Texas Red-
labeled anti-RBM3 antibody at increasing concentrations, added stepwise (6, 12, 21 nM – 80-100 min incubation of each concentration), C) Alexa
Fluor 488 labeled anti-mouse antibody after 3 h pre-incubation with anti-SATB2 antibody, D) direct binding of Texas Red-labeled anti-SATB2
antibody at increasing concentrations, added stepwise (6, 12, 21 nM – 80-100 min incubation of each concentration). In A and B, measurements
were done in nasopharynx (black solid line), urinary bladder (black dashed line), testis (grey solid line) and tonsil (grey dashed line). Measurements
C and D were performed in colon (black solid line), tonsil (black dashed line), liver (grey solid line) and heart muscle (grey dashed line). I = Fluorescent
intensity units.
Figure 4 The impact of tissue thickness, size and position on RT-IHC data. A) 1, 3 and 9 nM 125I-labeled anti-HER2 antibody subsequently
added in the same measurement at t = 0 h (1 nM), t = 20 h (3 nM) and t = 29 h (9 nM) to a dish containing SKOV3 xenograft (black) and mouse
liver (grey), with high and low HER2 expression respectively. The antibody solution was replaced with PBS + 1% BSA (t = 44 h) in order to study
the dissociation rate. B) 1 nM 125I-antibody binding to 10 μm (black solid line), 4 μm (black dotted line) and 2 μm (grey solid line) thick SKOV3
xenograft tissue slices. C) 1 nM 125I-antibody binding to SKOV3 xenograft tissues of different sizes: A full size tissue slice (black solid line), half a
slice (black dotted line) or a quarter of a slice (grey solid line). D) 1 nM 125I-antibody binding to SKOV3 xenografts positioned approximately
0-16 mm (black solid line), 4-20 mm (black dotted line), 8-24 mm (grey solid line) or 12-28 mm (grey dotted line) from the rim of the dish. The
detection area stretches from the rim and into approximately 20 mm of the dish. CPS = Counts per second.
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is far from saturated for the lower concentrations.
Studying the impact of tissue thickness, size and position
The binding of anti-HER2 antibody with the SKOV3
xenograft was detected in various conditions in order to
study the impact of tissue thickness, size and position.
The thickness of the tissue sections appears to have a
relatively small impact on the signal level in RT-IHC. 2
μm and 4 μm thicknesses resulted in almost identical
signal levels, while the 10 μm slices produced appro-
ximately 35% higher signals (Figure 4B). The different
tissue thicknesses were measured in parallel in one dish,
at two occasions (generating duplicates of each thick-
ness type).
The tissue slices were cut into different sizes (full size,
half a slice and a quarter of a slice) and measured in pa-
rallel in the same dish at two occasions. A correlation be-
tween signal level and tissue size was observed (Figure 4C).
The full sized slice (black solid line) produced approxi-
mately twice as high signal than the half slice (black dotted
line). However, the signal level from the half slice and the
quarter slice (grey solid line) were similar.
Positioning of the tissue section is relevant if this causes
some part of the tissue slice to be outside the detection
area, which stretches from the rim and into approximately
20 mm of the dish (Figure 4D) for LigandTracer Grey.
With 17 mm in length, the slices were completely or al-
most completely within the detection area when posi-
tioned 0 mm (black solid line) or 4 mm (black dotted line)
from the rim of the dish. This resulted in somewhat higher
signal levels for the 0 mm position. When positioned 8
mm (grey solid line) or 12 mm (grey dotted line) a signifi-
cant proportion of the tissue slices were undetected, pro-
ducing clearly lower signal heights.
Tissue thickness, size and position did not affect the
shape of the real-time binding curves, as observed after
data normalization (data not shown).
Discussion
Previous work on RT-IHC has been done with a single
antibody, through detection of radioactivity [9,11]. This re-
port summarizes results from several different real-time
IHC assays, using a series of tissues, labels and use of pri-
mary labeled antibodies or secondary antibody readout.
Thus, we have verified the work of Gedda et. al. and
showed that real-time IHC is generally applicable in hist-
ology, also for fluorescently labeled antibodies. Another
aim of this study was to investigate which conditions of
the tissue (thickness, size and position) that can have an
impact on the result and within which limits sufficiently
high signal levels are produced.
All antibody-antigen interactions investigated in this
study, both the primary antibody binding to its targetand the secondary antibody binding to the primary, re-
quire several hours to reach equilibrium at the concen-
trations used. This is in line with previous reports from
both general antibody binding and real-time IHC [9,23,24].
Common IHC protocols typically rely on short incubation
times (about 30 minutes) and low concentrations of anti-
body, meaning that the likelihood that equilibrium is
approached during incubation is low. This is probably one
complicating factor in the reproducibility of IHC because
if the assay is performed without reaching equilibrium,
small variations in incubation time and antibody concen-
tration may change the binding level of the antibody and
thereby alter the end result. It has further been observed
that the binding rate of the same antibody can vary be-
tween tissues, which will result in different staining inten-
sities if equilibrium is not reached, even if the antigen is
expressed to the same degree [11].
The results from the tissue staining were similar to
the results of the secondary antibody measured in
LigandTracer (Figure 3A, C). The low signal levels for
tonsil and liver pre-incubated with anti-SATB2 antibody
(Figure 3C) is likely the result of SATB2 being expressed
in only a small fraction of the tissue (Figure 1F, G).
There are differences between the results of the pri-
mary (Figure 3B, D) and secondary antibody (Figure 3A,
C) measurements. In the tissue panel used for RBM3,
testis had higher signals from primary labeled antibody
than from secondary read out (in comparison to other
tissues), and the same deviation was observed for liver
and heart muscle for SATB2. At this point we can only
observe that there is a discrepancy, finding out the ori-
gin of it is beyond the scope of this paper. One possible
reason is that the deviating tissues (testis, liver and heart
muscle) have low-affinity sites to which the primary
antibody binds, but also dissociates quickly after wash.
Such interactions with fast off-rate would remain un-
detected when using labeled secondary antibodies. These
kind of weak interactions have been noted in the field of
immunogenicity of therapeutic antibodies and proved
critical for understanding the biological action [25].
The HER2 binding antibody was included in this study
and labeled with 125I to facilitate comparison with previ-
ous work with RT-IHC [9,11]. Since both binding rate
and signal height is comparable with the published data
when using the same tissue types, the authors conclude
that their RT-IHC protocol is similar to the earlier setup.
Based on the results in Figures 2 and 3, a fluorescent
label would have worked just as well.
The impact of thickness, size and position were evalu-
ated in order to find optimal settings for the assay, as
well as to investigate how small differences between
tissue sections affect the signal height, curvature (inter-
action kinetics) and overall interpretation of RT-IHC
data.
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fected the signal level, as observed for the 10 μm sec-
tions. This is in line with what have been previously
observed for manual scoring [26]. Fortunately, this is a
property that can be controlled during processing, min-
imizing the risk of unwanted variation between samples
due to thickness. The authors suggest the use of 3 - 4
μm sections since this is a commonly used thickness
which also avoids waste of e.g. limited patient material.
If a binding would be difficult to detect due to e.g. low
expression levels, thicker sections can be used instead.
Tissue size has a clear impact on signal height, but the
relationship is not completely linear. The reason behind
the similar signal levels for the half and quarter sized
sections may be a heterogeneous distribution of the anti-
gen (HER2), i.e. if the total amount of antigen is similar
even though the tissue sizes are different. The overall
conclusion from the studies represented in Figure 4 is
that the signal height can be affected by tissue parame-
ters such as size and positioning. This must be taken
into consideration if the aim of RT-IHC is to use it as a
quantitative tool for the comparison of antigen expres-
sion, especially when using patient biopsy material where
the size and shape can vary. The strength of RT-IHC is
however likely not the objective analysis of signal level,
but rather the comparison of curvature, which was not
affected by the thickness, size or positioning. For ex-
ample, published data show that there is a correlation
between curve shape, corresponding to interaction kinet-
ics, and HER2 scoring [11]. A kinetic evaluation is inde-
pendent of signal amplitude, as long as the signal is
sufficient to trace the curvature. In this study the signal
was high enough for a clear binding trace, but for low
antigen expression it may be important to increase the
amplitude. Based on the results of Figure 4, this is
possible by e.g. using larger tissue sections.
One field where RT-IHC may be useful is in the devel-
opment of conventional IHC. The ability to follow mo-
lecular interactions minute by minute is a help when
developing assays, fine-tuning performance and trouble-
shooting problems. One obvious drawback of the RT-
IHC method is the lack of spatial resolution, since one
average binding trace is collected for the complete tissue
section. As evident from the IHC results (Figure 1), it is
not always the average signal from the complete section
that is of interest. Hence RT-IHC should be seen as a
complement to conventional IHC, where one method
provides the temporal dimension and the other the
spatial dimension.Conclusions
Real-time immunohistochemistry is confirmed as a gen-
eric tool for the development of conventional IHC. Wewill continue to explore the possibilities of RT-IHC in
combination with conventional IHC in our laboratory.
Methods
Tissue samples and reagents
Tissue samples of nasopharynx, urinary bladder, testis,
tonsil, colon, liver and heart muscle were obtained under
the ethical permit of 2005:338, 2007/159 and 02-577.
Xenografts of the human ovarian carcinoma cell line
SKOV3 (HTB-77, ATCC, Rocksville, MD, USA) were used
to represent high expression of HER2. The xenografts were
formed by s.c. inoculation in the right posterior leg of
BALB/c (nu/nu) mice (M&B, Ry, Denmark) injecting 107
SKOV3 cells in 0.1 ml medium, which comply with current
Swedish law and done with permission from the local com-
mittee of animal research ethics. Once the xenografts had
grown to a size of approximately 1 cm in diameter, tumors
were excised and fixated in 4% phosphate-buffered for-
malin. Mouse liver, used as a HER2 low expressing tissue,
was removed from healthy animals and fixated. Tissue was
dehydrated for 15 + 15 min in 70% EtOH, 30 min in 90%
EtOH, 15 + 15 min in 95% EtOH, 15 + 15 min in 99%
EtOH and thereafter embedded in paraffin and stored until
further use.
Mouse monoclonal antibodies against RBM3 (Product
ID: AMAb90655, Clone ID CL0296) and SATB (Product
ID: AMAb90635, Clone ID CL0276) were obtained from
Atlas Antibodies AB (Stockholm, Sweden). The Alexa
Fluor 488 labeled goat anti-mouse IgG (Product ID:
A11001) used as a secondary antibody was from Invitro-
gen (Carlsbad, California). The polyclonal antibody di-
rected against HER2 (Product ID: A0485) was obtained
from DAKO (Glostrup, Denmark). Although being of
polyclonal nature, the authors have previously demon-
strated that this antibody has a highly monoclonal inter-
action behavior, i.e. one single dominating interaction with
defined kinetic properties was observed when binding to
the SKOV3 xenograft [11].
Antibody labeling
Primary antibodies for SATB2 and RBM3 were labeled
with Texas Red to the lysine residues according to the
manufacturer’s instructions. The fluorophore was dis-
solved in DMSO and mixed with 10 μg of antibody in a
total volume of approximately 100 μl borat buffer pH 9.
After 60-90 minutes of incubation at 37°C the unreacted
dye was separated from the labeled antibody using a
NAP-5 column. The labeled antibodies were wrapped in
tin foil and stored in the freezer. The secondary antibody
(anti-mouse) was labeled with Alexa Fluor 488 by the
manufacturer.
The anti-HER2 antibody was labeled with 125I accord-
ing to the CAT-protocol [27], which causes 125I to bind
to tyrosine residues on the antibody.
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Tissue sections (4 μm thick) were placed on FROST glass
followed by heat incubation (50°C) over night. The sections
were deparaffinized in a Leica (Wetzlar, Germany) auto-
stainer and pressure boiled in a decloaking chamber from
Biocare Medical (Concord, CA, USA) in TRS buffer pH 6.
Finally, the tissue sections were manually scored, essen-
tially as previously described [28]. In brief, tissue sections
were incubated with primary antibody and a dextran poly-
mer visualization system (UltraVision LP HRP polymer,
Thermo Scientific, Waltham, MA, USA) for 30 min each
at room temperature followed by incubation for 10 min
with chromogen diaminobenzidine (Thermo Scientific,
Waltham, MA, USA). All incubations were followed by a
rinse in wash buffer (Thermo Scientific, Waltham, MA,
USA). Slides were counterstained in Mayer’s hematoxylin
(Histolab, Gothenburg, Sweden) for 5 min. No blocking
step was included, which is in line with the findings of
Buchwalow and colleagues [29].
RT-IHC analysis
Multiple tissues sections were placed evenly distributed
along the rim of a glass petri dish essentially as de-
scribed previously [9]. One position was always left
tissue free, to be used as a background reference.
Prior to measurement, dishes were deparaffinized in
xylen 20 + 5 min, 99.5% EtOH 20 + 5 min, 95% EtOH 20 +
5 min, 70% 20 min and kept in dH2O until pressure boiled
as described above. Dishes were left to cool off in running
dH2O for a couple of minutes after pressure boiling. To
avoid antigen degradation or tissue sections releasing from
the glass dish, dishes were used the day of preparation.
The interaction of the antibody with its antigen was
measured in LigandTracer Green or LigandTracer Grey
(Ridgeview Instruments AB, Uppsala, Sweden), essentially
as described by Björke [12], by monitoring either fluores-
cent (LigandTracer Green) or radioactive (LigandTracer
Grey) labels. In brief, each dish was first rinsed gently with
4 ml PBS with 1% BSA for 15 minutes to coat all glass
surfaces with protein, followed by mounting the dish in
the instrument and adding 3 ml of fresh PBS with 1%
BSA. After a short baseline measurement, labeled antibody
was added and binding to the tissue sections were moni-
tored during incubation. In some of the measurements
(Figure 4), the incubation was followed by a dissociation
measurement in which the antibody solution had been
replaced with fresh PBS with 1% BSA. Corrections for
nuclide decay were done automatically in the software
controlling the instrument.
A few different antibody concentrations were tested for
adequacy in RT-IHC. In the end, concentrations similar to
the recommendations of the manufacturer (when avail-
able) were selected also for RT-IHC, since these resulted
in detectable signals during LigandTracer measurements.Interaction measurements of three types were con-
ducted: (A) The tissue was pre-incubated with 8 nM
unlabeled primary antibody followed by the detection of
6.5 nM labeled secondary antibody (SATB2, RBM3 –
Figures 2 and 3A, C). (B) The tissue was used for direct
detection of 6, 12 and 21 nM fluorescently labeled pri-
mary antibody, subsequently added (SATB2, RBM3 –
Figure 3B, D). (C) The association and dissociation of
antibody (1 nM or 1;3;9 nM) were monitored continu-
ously (HER2 – Figure 4), using different tissue thick-
nesses (2 μm, 4 μm and 10 μm), sizes (100%, 50% and
25% the size of consecutive tissue slices) and positions
(0 mm, 4 mm, 8 or 12 mm from the rim of the dish).
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